• This large-scale public-private research initiative will provide new insights into the mechanisms of response and non-response to treatment within and across seven different immune-mediated diseases through integrated, cross-disease analysis of the most state-of-the-art profiling technologies
  • 3TR will have access to an unprecedented quantity of clinical data and samples of more than 50,000 patients across 50 clinical trials, ultimately aiming to discover and verify stratification biomarkers to improve patient management
  • The project unites renowned, interdisciplinary experts from 69 academic and industrial partner institutions covering 15 European countries
  • 3TR is funded with a total of over € 80 mio over the next seven years by IMI2 – a joint undertaking of the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA) 


Visit 3TR website.